無料プレビュー

Reata Pharmaceuticals, Inc. (RETA) · NASDAQ Global Market

プロフィール

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kid

主要指標

株価: $172.36 (+0.02%)
時価総額: 66億ドル
PER（今期予想）: —
PBR: -95.3
配当利回り: —
52週レンジ: $21.83 – $172.46
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2024-08-05 · 更新: 2026-10-09